Vaasa Central Hospital — Clinical Trial Site

26 Registered trials

14 Currently recruiting

Organisation

Vaasa Central Hospital

Location

Vaasa, Finland

Identifier

ORG-100044748

Address

Hietalahdenkatu 2-4, 65130, Finland

Departments

358006: Oncology
Abdominal surgery
Clinical Oncology
Department of Clinical Oncology
Department of Clinical Oncology Loc. 2
Department of Clinical Ongology
Department of Nephrology
Department of Oncology
NA
Neurocenter
Onchology
Oncology department
Oncology Outpatient Clinic and Day Department
Ongology
Onkologian poliklinikka
Onkologiska kliniken
Syövänhoito

Clinical trials at this site (26)

Search interface

A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting

2025-521939-36-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 4 2026-03-03
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and impaired Renal functiOn (INCAR… Recruiting

2024-512084-31-00 Patients requiring emergency abdominal or body CT with 6 2025-06-24
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting

2023-506288-33-00 Metastatic castration resistant prostate cancer (mCRPC) 9 2025-03-03
RAXO trial - A population-based prospective study to evaluate clinical behaviour, resectability and survival in metastatic colorectal cancer… Recruiting

2024-520288-15-00 Metastatic or locally advanced inoperable colorectal ca 6 2025-01-25
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti… Ended

2024-512439-54-01 Non-small cell lung cancer (NSCLC) 4 2024-07-24
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 5 2020-11-12